INTRODUCTION: Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD). METHODS: Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods. RESULTS: Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised ~ 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity. CONCLUSIONS: Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.

Department of Biomedicine Health Aarhus University Aarhus Denmark

Department of Clinical Microbiology National Reference Center Streptococcus Agalactiae University Hospital Center of Liege Liege Belgium

Department of Infectious Diseases Istituto Superiore Di Sanità Rome Italy

Department of Obstetrics and Gynecology University Medical Center Medical Faculty University of Freiburg Freiburg Germany

Department of Pediatrics and Adolescent Medicine University Medical Center Medical Faculty University of Freiburg Freiburg Germany

Department of Pediatrics University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany

GSK Vaccines Siena Italy

National Center of Infectious and Parasitic Diseases Sofia Bulgaria

National Institute of Public Health Prague Czech Republic

Servicio Andaluz de Salud Hospital Universitario Virgen de Las Nieves Granada Spain

UK Health Security Agency London UK

Zobrazit více v PubMed

Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. Vaccine. 2013;31:D31-42. 10.1016/j.vaccine.2013.05.012. PubMed

Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342:15–20. 10.1056/NEJM200001063420103. PubMed

Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AKM, Cousens S, Heath PT. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379:547–56. 10.1016/S0140-6736(11)61651-6. PubMed

Puopolo KM, Lynfield R, Cummings JJ, Hand I, Adams-Chapman I, Poindexter B, Stewart DL, Aucott SW, Goldsmith JP, Mowitz M, Watterberg K, Maldonado YA, Zaoutis TE, Banerjee R, Barnett ED, Campbell JD, Gerber JS, Kourtis AP, Munoz FM, Nolt D, Nyquist AC, O’Leary ST, Sawyer MH, Steinbach WJ, Zangwill K, Committee on fetus and newborn, Committee on infectious diseases. Management of infants at risk for group B Streptococcal disease. Pediatrics. 2019;144:e20191881. 10.1542/peds.2019-1881. PubMed

Lohrmann F, Hufnagel M, Kunze M, Afshar B, Creti R, Detcheva A, Kozakova J, Rodriguez-Granger J, Sørensen UBS, Margarit I, Maione D, Rinaudo D, Orefici G, Telford J, de la Rosa FM, Kilian M, Efstratiou A, Berner R, Melin P. Neonatal invasive disease caused by Streptococcus agalactiae in Europe: the DEVANI multi-center study. Infection. 2023;51:981–91. 10.1007/s15010-022-01965-x. PubMed PMC

Schrag SJ, Verani J. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013. 10.1016/j.vaccine.2012.11.056. PubMed PMC

ACOG (American Congress of Obstetricians and Gynecologists) Committee on Obstetric Practice. ACOG committee opinion no 485: prevention of early-onset group B streptococcal disease in newborns. Obstet Gynecol. 2011;117:1019–27. 10.1097/AOG.0b013e318219229b. PMID: 31977793. PubMed

Verani M JR, L S, S.J. (2010) Division of bacterial diseases, national center for immunization and respiratory diseases, centers for disease control and prevention (CDC. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC 59:1–36

Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revis Guidel CDC Morb Mort Wkly Rep Recomm Rep. 2002;51:1–22. PubMed

Hughes RG, Brocklehurst P, Steer PJ, Heath P. Stenson BM on behalf of the royal college of obstetricians and gynaecologists prevention of early-onset neonatal group B streptococcal disease. Green-top Guidel. 2017. 10.1111/1471-0528.14821.

Kunze M, Ziegler A, Fluegge K, Hentschel R, Proempeler H, Berner R. Colonization, serotypes and transmission rates of group B streptococci in pregnant women and their infants born at a single university center in Germany. J Perinat Med. 2011;39:417–22. 10.1515/jpm.2011.037. PubMed

Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, Melin P, Decheva A, Orefici G, Poyart C, Telford J, Efstratiou A, Killian M, Krizova P, Baldassarri L, Spellerberg B, Puertas A, Rosa-Fraile M. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin Microbiol Infect Dis. 2012;31:2097–104. 10.1007/s10096-012-1559-0. PubMed

Bekker V, Bijlsma MW, van de Beek D, Kuijpers TW, van der Ende A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis. 2014;14:1083–9. 10.1016/S1473-3099(14)70919-3. PubMed

Russell NJ, Seale AC, O’Sullivan C, Le Doare K, Heath PT, Lawn JE, Bartlett L, Cutland C, Gravett M, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Baker CJ. Risk of early-onset neonatal group b streptococcal disease with maternal colonization worldwide systematic review meta-analyses. Clin Infect Dis. 2017;65:S152–9. 10.1093/cid/cix655. PubMed PMC

Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, Melin P, Decheva A, Orefici G, Poyart C, Telford J, Efstratiou A, Killian M, Krizova P, Baldassarri L, Spellerberg B, Puertas A, Rosa-Fraile M. Prevention of group B streptococcal neonatal disease revisited DEVANI European project. Eur J Clin Microbiol Infect Dis. 2012;31:2097–104. 10.1007/s10096-012-1559-0. PubMed

Fabbrini M, Rigat F, Rinaudo CD, Passalaqua I, Khacheh S, Creti R, Baldassarri L, Carboni F, Anderloni G, Rosini R, Maione D, Grandi G, Telford JL, Margarit I. The protective value of maternal group B Streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera. Clin Infect Dis. 2016;63:746–53. 10.1093/cid/ciw377. PubMed

Afshar B, Broughton K, Creti R, Decheva A, Hufnagel M, Kriz P, Lambertsen L, Lovgren M, Melin P, Orefici G, Poyart C, Radtke A, Rodriguez-Granger J, Sørensen UBS, Telford J, Valinsky L, Zachariadou L, Efstratiou A, Members of the DEVANI Study Group. International external quality assurance for laboratory identification and typing of Streptococcus agalactiae (group B streptococci). J Clin Microbiol. 2011;49:1475–82. PubMed PMC

Yao K, Poulsen K, Maione D, Rinaudo CD, Baldassarri L, Telford JL, Sørensen UBS, Kilian M, Members of the DEVANI Study Group. Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination. J Clin Microbiol. 2013;51:503–7. 10.1128/JCM.02417-12. PubMed PMC

Rosini R, Campisi E, De Chiara M, Tettelin H, Rinaudo D, Toniolo C, Metruccio M, Guidotti S, Sørensen UBS, Kilian M, Ramirez M, Janulczyk R, Donati C, Grandi G, Margarit I, DEVANI Consortium. Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population. PLoS ONE. 2015;10:e0125985. 10.1371/journal.pone.0125985. PubMed PMC

Lohrmann F, Berg A, Wicker E, Imm A, Krause G, Zürn K, Berner R, Hufnagel M, Lander F. Prevalence of capsular serotype, Pilus Island distribution, and antibiotic resistance in pediatric and adult invasive Group B Streptococcus isolates: data from a nationwide prospective surveillance study in Germany. Pediatr Infect Dis J. 2021;40:76–82. 10.1097/INF.0000000000002943. PubMed

Creti R, Imperi M, Berardi A, Pataracchia M, Recchia S, Alfarone G, Baldassarri L, Italian Neonatal GBS Infections Working Group. Neonatal group B streptococcus infections: prevention strategies, clinical and microbiologic characteristics in 7 years of surveillance. Pediatr Infect Dis J. 2017;36:256–62. 10.1097/INF.0000000000001414. PubMed

Absalon J, Segall N, Block SL, Center KJ, Scully IL, Giardina PC, Peterson J, Watson WJ, Gruber WC, Jansen KU, Peng Y, Munson S, Pavliakova D, Scott DA, Anderson AS. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect Dis. 2021;21:263–74. 10.1016/S1473-3099(20)30478-3. PubMed PMC

Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21:3468–72. 10.1016/s0264-410x(03)00353-0. PubMed

Swamy GK, Metz TD, Edwards KM, Soper DE, Beigi RH, Campbell JD, Grassano L, Buffi G, Dreisbach A, Margarit I, Karsten A, Henry O, Lattanzi M, Bebia Z. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: results from a randomized placebo-controlled phase II trial. Vaccine. 2020;38:6930–40. 10.1016/j.vaccine.2020.08.056. PubMed

Madhi SA, Anderson AS, Absalon J, Radley D, Simon R, Jongihlati B, Strehlau R, van Niekerk AM, Izu A, Naidoo N, Kwatra G, Ramsamy Y, Said M, Jones S, Jose L, Fairlie L, Barnabas SL, Newton R, Munson S, Jefferies Z, Pavliakova D, Silmon de Monerri NC, Gomme E, Perez JL, Scott DA, Gruber WC, Jansen KU. Potential for maternally administered vaccine for infant group B streptococcus. N Engl J Med. 2023;389:215–27. 10.1056/NEJMoa2116045. PubMed

Imperi M, Pataracchia M, Alfarone G, Baldassarri L, Orefici G, Creti R. A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae. J Microbiol Methods. 2010;80:212–4. 10.1016/j.mimet.2009.11.010. PubMed

Prevention of group B streptococcal early-onset disease in newborns: ACOG committee opinion summary, Number 797. Obstet Gynecol. 2020;135(2):489–492. 10.1097/AOG.0000000000003669. PubMed

Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, Madhi SA, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Rubens CE, Saha SK, Sobanjo-Ter Meulen A, Vekemans J, Schrag S, Infant GBS Disease Investigator Group. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65:S172. 10.1093/cid/cix656. PubMed PMC

R Core Team (2024) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria

Vieira LL, Perez AV, Machado MM, Kayser ML, Vettori DV, Alegretti AP, Ferreira CF, Vettorazzi J, Valério EG. Group B Streptococcus detection in pregnant women: comparison of qPCR assay, culture, and the Xpert GBS rapid test. BMC Pregnancy Childbirth. 2019;19:532. 10.1186/s12884-019-2681-0. PubMed PMC

Hansen SM, Uldbjerg N, Kilian M, Sørensen UBS. Dynamics of Streptococcus agalactiae colonization in women during and after pregnancy and in their infants. J Clin Microbiol. 2004;42:83–9. 10.1128/JCM.42.1.83-89.2004. PubMed PMC

Kunze M, Zumstein K, Markfeld-Erol F, Elling R, Lander F, Prömpeler H, Berner R, Hufnagel M. Comparison of pre- and intrapartum screening of group B streptococci and adherence to screening guidelines: a cohort study. Eur J Pediatr. 2015;174:827–35. 10.1007/s00431-015-2548-y. PubMed

Kjerulff KH, Attanasio LB, Vanderlaan J, Sznajder KK. Timing of hospital admission at first childbirth: A prospective cohort study. PLoS ONE. 2023;18:e0281707. 10.1371/journal.pone.0281707. PubMed PMC

Williams M, Zantow E, Turrentine M. Cost effectiveness of latest recommendations for group B streptococci screening in the United States. Obstet Gynecol. 2020;135:789–98. PubMed

WHO Group B Streptococcus (GBS). https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/group-b-streptococcus-(gbs). Accessed 11 Jul 2024